Comparison of Once Daily Versus 8 Hour Dosing of Gentamicin for the Treatment of Intrapartum Chorioamnionitis
Information source: Stanford University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Chorioamnionitis
Intervention: gentamicin (Drug)
Phase: N/A
Status: Completed
Sponsored by: Stanford University Official(s) and/or principal investigator(s): Yasser Yehia El-Sayed, Principal Investigator, Affiliation: Stanford University
Summary
To compare once daily versus 8 hour dosing of gentamicin for the treatment of
chorioamnionitis.
Clinical Details
Official title: Comparison of Once Daily Versus 8 Hour Dosing of Gentamicin for the Treatment of Intrapartum Chorioamnionitis
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Primary outcome: Afebrile at 24 hours and no endometritis
Secondary outcome: Neonatal outcomes
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- clinical diagnosis of chorioamnionitis
Exclusion Criteria:
- maternal renal disease, intrauterine fetal death, allergy to gentamicin
Locations and Contacts
Stanford University School of Medicine, Stanford, California 94305, United States
Additional Information
Starting date: June 2004
Last updated: June 13, 2011
|